Clinical characteristics of refractory myasthenia gravis patients.
Open Access
- 13 June 2013
- journal article
- Vol. 86 (2), 255-60
Abstract
A subset of myasthenia gravis (MG) patients is refractory to standard therapies. Identifying the characteristics of this population is essential as newer treatment strategies emerge that may be more effective in this group. The aim of our study is to describe the clinical features of refractory MG patients and compare them to those of non-refractory patients. A retrospective chart review was completed of 128 MG patients referred to a tertiary neuromuscular clinic from 2003 to 2011. Patients were classified as refractory or non-refractory based on predefined criteria, and clinical features were compared. Nineteen out of 128 patients were classified as refractory (14.8 percent). Compared to the non-refractory patients, the refractory patients were more likely to be younger at onset, female, thymomatous, and MuSK-antibody positive. Refractory MG patients represent a small but distinct group for whom exploring newer therapeutic approaches and immunopathologic differences is warranted.Keywords
This publication has 13 references indexed in Scilit:
- Myasthenia GravisSeminars in Neurology, 2012
- Response of patients with refractory myasthenia gravis to rituximab: a retrospective studyTherapeutic Advances in Neurological Disorders, 2011
- Update on muscle-specific tyrosine kinase antibody positive myasthenia gravisCurrent Opinion in Neurology, 2010
- Rituximab in the management of refractory myasthenia gravisMuscle & Nerve, 2009
- Autoimmune myasthenia gravis: emerging clinical and biological heterogeneityThe Lancet Neurology, 2009
- Rebooting the Immune System with High‐Dose Cyclophosphamide for Treatment of Refractory Myasthenia GravisAnnals of the New York Academy of Sciences, 2008
- Response to Therapy in Myasthenia Gravis with Anti‐MuSK AntibodiesAnnals of the New York Academy of Sciences, 2008
- Mycophenolate mofetil – as an adjunctive immunosuppressive therapy in refractory myasthenia gravis: The Singapore experienceJournal of Clinical Neuroscience, 2007
- High dose cyclophosphamide for severe refractory myasthenia gravisJournal of Neurology, Neurosurgery & Psychiatry, 2004
- Myasthenia GravisThe New England Journal of Medicine, 1994